Clarify the Role of Mounjaro for Type 2 Diabetes
July 2022
You’ll hear buzz about new injectable Mounjaro (tirzepatide)...the first “twincretin” for type 2 diabetes.
Think of Mounjaro as similar to a glucagon-like peptide-1 (GLP-1) agonist...but it’s also a glucose-dependent insulinotropic polypeptide (GIP) agonist. More twincretins are in the works.
GLP-1 and GIP stimulate insulin release, increase satiety, and decrease glucose production.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote